Momester Nasal (Mometasone Furoate)

Mometasone furoate, the active ingredient in Momester Nasal, is a corticosteroid presented as a nasal spray for nasal administration. It reduces inflammation of the nasal mucosa and is indicated for the management of allergic rhinitis and nasal polyps in adults and children when prescribed by a healthcare professional.

GNH USA supplies Momester Nasal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines across global markets.

Momester Nasal, a nasal corticosteroid, is employed to manage inflammatory conditions of the nasal passages.

- Allergic rhinitis: alleviates nasal congestion, itching, sneezing and rhinorrhea. - Nasal polyps: reduces polyp size and improves nasal airflow.

Adverse reactions to Momester Nasal are generally localized to the nasal cavity, but systemic effects can occur rarely.

Common Side Effects: - Nasal irritation or burning. - Dryness of nasal passages. - Epistaxis (nosebleeds). - Headache.

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use. - Cataracts or glaucoma. - Fungal infection of the nasal mucosa.

Before prescribing Momester Nasal, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: safety not established; use only if benefit outweighs risk. - Lactation: unknown; assess risk versus benefit. - Pediatric use: limit duration and monitor growth when used in children. - Local infection: avoid if active nasal infection is present. - Concomitant systemic corticosteroids: increase risk of systemic effects. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Mometasone furoate may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Systemic corticosteroids: additive systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase local exposure.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly raise exposure. - Antifungal azoles (e.g., fluconazole): potential increase in drug levels. - HIV protease inhibitors (e.g., ritonavir): may elevate concentrations. - Immunosuppressants (e.g., cyclosporine): monitor for enhanced immunosuppression.